open access

Vol 12, No 5 (2016)
Research paper
Published online: 2017-03-08
Get Citation

The activity of pembrolizumab in therapy of pretreated metastatic melanomas — two centres’ experience

Paweł Rogala, Joanna Stępniak, Tomasz Świtaj, Ewa Kalinka-Warzocha, Katarzyna Kozak, Hanna Koseła-Paterczyk, Piotr Rutkowski
DOI: 10.5603/OCP.2016.0008
·
Oncol Clin Pract 2016;12(5):161-166.

open access

Vol 12, No 5 (2016)
ORIGINAL ARTICLES
Published online: 2017-03-08

Abstract

Introduction. Pembrolizumab [programmed death 1 (PD-1) checkpoint inhibitor] mediates durable responses and prolongs survival in patients with advanced melanomas. We assessed the efficacy and safety of pembrolizumab in pretreated metastatic melanoma patients outside clinical trials.

Methods. Fifty-four patients (median age 57 years; range 18–77) after progression on previous therapy (at least ipilimumab) in metastatic setting were administered pembrolizumab at a registered dose 2 mg/kg every three weeks and were observed for progression-free survival (PFS), overall survival (OS), responses, and toxicity. Median follow-up time for survivors was 8.5 months.

Results. In all except six cases pembrolizumab was given in at least third line of systemic therapy. All patients (except two patients with ocular melanomas) had cutaneous origin of the primary; 16 were BRAF-positive (30%), 42 patients were in M1c stage (78%); and 27 patients had increased initial LDH level (50%). The clinical benefit of pembrolizumab therapy was 50% with one complete remission, seven partial remissions, and 19 stable diseases. Thirty-six patients received more than four doses of the drug; 13 patients still remain on treatment. Median OS was not reached. The estimated one-year OS was 48%. We observed no differences in OS between BRAF-positive and BRAF-negative cases. Poorer OS was found in patients with initially increased LDH level (p = 0.04), and slightly worse results were seen for patients treated with more than three lines of therapy and in M1c stage. Median PFS was 5.6 months, estimated one-year PFS rate was 40%, and better PFS was observed for patients with initially normal LDH (7.5 vs. 4.5 months; p = 0.02). The treatment was well tolerated with adverse events (AE) occurring in 14 patients (26%), but in only three cases grade 3 AEs were observed (6%): diarrhoea, diabetes mellitus, pneumonitis.

Conclusions. Pembrolizumab confirmed its activity and safety outside clinical trials in therapy of pretreated metastatic melanomas. Anti-PD-1 inhibitors are the preferred treatment option in advanced melanoma management.

Abstract

Introduction. Pembrolizumab [programmed death 1 (PD-1) checkpoint inhibitor] mediates durable responses and prolongs survival in patients with advanced melanomas. We assessed the efficacy and safety of pembrolizumab in pretreated metastatic melanoma patients outside clinical trials.

Methods. Fifty-four patients (median age 57 years; range 18–77) after progression on previous therapy (at least ipilimumab) in metastatic setting were administered pembrolizumab at a registered dose 2 mg/kg every three weeks and were observed for progression-free survival (PFS), overall survival (OS), responses, and toxicity. Median follow-up time for survivors was 8.5 months.

Results. In all except six cases pembrolizumab was given in at least third line of systemic therapy. All patients (except two patients with ocular melanomas) had cutaneous origin of the primary; 16 were BRAF-positive (30%), 42 patients were in M1c stage (78%); and 27 patients had increased initial LDH level (50%). The clinical benefit of pembrolizumab therapy was 50% with one complete remission, seven partial remissions, and 19 stable diseases. Thirty-six patients received more than four doses of the drug; 13 patients still remain on treatment. Median OS was not reached. The estimated one-year OS was 48%. We observed no differences in OS between BRAF-positive and BRAF-negative cases. Poorer OS was found in patients with initially increased LDH level (p = 0.04), and slightly worse results were seen for patients treated with more than three lines of therapy and in M1c stage. Median PFS was 5.6 months, estimated one-year PFS rate was 40%, and better PFS was observed for patients with initially normal LDH (7.5 vs. 4.5 months; p = 0.02). The treatment was well tolerated with adverse events (AE) occurring in 14 patients (26%), but in only three cases grade 3 AEs were observed (6%): diarrhoea, diabetes mellitus, pneumonitis.

Conclusions. Pembrolizumab confirmed its activity and safety outside clinical trials in therapy of pretreated metastatic melanomas. Anti-PD-1 inhibitors are the preferred treatment option in advanced melanoma management.

Get Citation

Keywords

pembrolizumab, anti-PD-1 inhibitors

About this article
Title

The activity of pembrolizumab in therapy of pretreated metastatic melanomas — two centres’ experience

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 5 (2016)

Article type

Research paper

Pages

161-166

Published online

2017-03-08

DOI

10.5603/OCP.2016.0008

Bibliographic record

Oncol Clin Pract 2016;12(5):161-166.

Keywords

pembrolizumab
anti-PD-1 inhibitors

Authors

Paweł Rogala
Joanna Stępniak
Tomasz Świtaj
Ewa Kalinka-Warzocha
Katarzyna Kozak
Hanna Koseła-Paterczyk
Piotr Rutkowski

References (15)
  1. Rutkowski P. Nowe terapie w czerniakach. Via Medica, Gdańsk 2016.
  2. Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther. 2015; 37(4): 764–782.
  3. Rutkowski P, Ługowska I, Świtaj T. Pembrolizumab. Biblioteka czasopisma Onkologia w Praktyce Klinicznej. Via Medica, Gdańsk 2015.
  4. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948): 1109–1117.
  5. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2): 134–144.
  6. Patnaik A, Kang SP, Rasco D, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015; 21(19): 4286–4293.
  7. Daud A, Ribas A, Robert C et al. Long-term efficacy of pembrolizumab (pembro;MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO 2015, abstract nr 9005.
  8. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16(8): 908–918.
  9. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
  10. Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016; 34(34): 4102–4109.
  11. Charakterystyka Produktu Leczniczego Keytruda, EMA 2016.
  12. Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016; 26(3): 300–303.
  13. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015; 112(9): 1421–1427.
  14. Dummer R. Cutaneous Melanoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2015; 26(suppl. 5): v126–v132.
  15. Melanoma. NCCN.org (03.2016).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl